The Trump administration has launched its most sweeping effort yet to halt transgender procedures on minors by threatening to cut off federal dollars from hospitals that perform them.
Story Snapshot
- HHS proposes rules to deny Medicare, Medicaid and CHIP funds to hospitals providing gender-transition procedures to minors.
- Supporters say the move protects children from irreversible “sex-rejecting” interventions and medical malpractice.
- Major medical groups and LGBTQ advocates claim the rules endanger vulnerable youth and defy their treatment guidelines.
- The proposals face a long rulemaking process, likely court battles, and intense state-level fallout.
Trump administration targets federal funding for transgender procedures on minors
The U.S. Department of Health and Human Services announced a package of regulatory proposals aimed at effectively banning gender-affirming care for minors wherever federal health dollars are involved.
The measures would bar federal Medicaid funds from paying for puberty blockers, cross-sex hormones or surgeries for children, and would cut Medicare and Medicaid payments to hospitals that offer those procedures to patients under 18. Officials framed the move as child protection, not budget cutting.
Health and Human Services Secretary Robert F. Kennedy Jr. described gender-transition interventions for minors as “not medicine” but “malpractice,” arguing that “sex-rejecting procedures rob children of their futures.”
The proposals represent the most aggressive federal action to date against puberty blockers, hormone therapy and surgical procedures for transgender-identifying youth.
By tying compliance to federal reimbursements, the administration is using its strongest financial lever to pressure hospitals and clinics that participate in the nation’s largest public health programs.
Trump administration unveils proposals to cut off transgender care for minors https://t.co/dYcUQa635D
— CBS Mornings (@CBSMornings) December 18, 2025
Hospitals, states and federal leverage over children’s medicine
Nearly all U.S. hospitals rely on Medicare and Medicaid reimbursements, which cover seniors, people with disabilities and low-income Americans. If finalized, the new rules would force facilities that continue providing gender-affirming care to minors to risk losing critical federal funding streams, a financial hit most systems cannot absorb.
The same conditions would extend to the State Children’s Health Insurance Program for patients under 19, magnifying pressure on pediatric providers in states where such treatments remain legal.
Medicaid programs in just under half of states still cover gender-affirming care, while at least 27 states have already enacted laws restricting or banning these treatments for minors.
A recent Supreme Court decision upholding Tennessee’s SB1 law, which bars puberty blockers and hormones for transgender adolescents, signals that many of those state laws are likely to survive legal scrutiny.
The new HHS proposals would overlay a federal funding penalty on top of that state patchwork, narrowing access even in states that still allow and subsidize such care.
Regulatory steps, legal uncertainty and federal rulemaking hurdles
The administration’s proposals are not yet final or legally binding. Federal agencies must complete a lengthy rulemaking process that includes publishing draft rules, accepting public comment, analyzing feedback and issuing revised final regulations.
That process often takes months or longer and frequently triggers litigation from affected groups. Advocates for transgender youth and major medical organizations are expected to challenge these rules in court, arguing they unlawfully restrict standard medical practice and discriminate against a defined patient group.
Opponents warn that even before finalization, the policy signals will chill medical practice. Many hospitals have already scaled back or stopped gender-transition services for minors in anticipation of federal action and potential liability.
Administrators must weigh offering controversial care against risking their institution’s financial viability. That dynamic effectively narrows options for families without formally banning procedures nationwide, as risk-averse hospital boards move to comply ahead of any enforcement timetable.
Redefining disability and policing gender-transition products
Alongside the funding proposals, Kennedy said HHS’s Office for Civil Rights will pursue a rule excluding gender dysphoria from the federal definition of disability.
Removing that diagnosis from disability protections would weaken legal claims that transgender-identifying patients have under existing civil rights statutes in health care and other settings.
The step fits a broader administration effort to codify a biological, two-sex view of law and policy, starting from Trump’s first-day executive order recognizing only male and female.
In a coordinated action, the Food and Drug Administration issued warning letters to a dozen companies marketing chest-binding garments and related products commonly used by people with gender dysphoria.
Manufacturers such as GenderBender LLC and TomboyX were told that chest binders may only be legally marketed for FDA-approved medical uses, like post-mastectomy recovery.
Regulators signaled they view binders as medical devices subject to oversight, not lifestyle apparel, sharpening federal scrutiny on the broader ecosystem around youth gender transition.
Supporters frame protections for children, critics warn of harm
Centers for Medicare and Medicaid Services administrator Dr. Mehmet Oz characterized pediatric gender-transition treatments as “a Band-Aid on a much deeper pathology,” saying children with gender dysphoria are “confused, lost and need help.”
Supporters argue that halting irreversible medical interventions upholds basic medical ethics, parental concerns and a cautious approach to developing brains and bodies.
They emphasize that permanent changes like sterilization or loss of sexual function should not be decisions made before adulthood.
Transgender advocates and many medical organizations sharply dispute the administration’s stance. Leaders at groups such as The Trevor Project argue that legislative and regulatory pushes to “strip transgender and nonbinary youth of the health care they need” create a dangerous, one-size-fits-all federal mandate.
The American Medical Association and allied professional bodies have urged governments not to restrict access to gender-affirming care, warning that blanket bans ignore individualized clinical judgment and could increase mental health risks for vulnerable youth.
Public opinion, Congress and the broader cultural clash
Polling from the Associated Press-NORC Center for Public Affairs Research in May found about half of U.S. adults approved of how Trump was handling transgender issues.
That split highlights a country deeply divided yet increasingly skeptical of aggressive medical interventions on minors. At the news conference, detransitioned activist Chloe Cole thanked the administration, saying cries for help from young people who regretted their transitions “have finally been heard,” reinforcing the White House’s framing of the issue as protecting children from irreversible harm.
On Capitol Hill, related legislation is moving alongside the regulatory push. The House recently passed a bill exposing providers who offer gender-transition treatments to minors to potential prison time, sending it to the Senate for consideration. Another House measure would bar Medicaid coverage for gender-affirming care for children.
Together with Trump’s earlier executive orders cutting federal support for youth transitions and barring transgender participation in girls’ and women’s sports, the administration’s latest move underscores an ongoing effort to draw firm legal and financial lines around gender ideology and children.
